Jazz Pharmaceuticals plc Undistributed Earnings of Foreign Subsidiaries
Jazz Pharmaceuticals plc (JAZZ) had Undistributed Earnings of Foreign Subsidiaries of $1.60 billion as of 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Notes › Income Taxes
us-gaap:UndistributedEarningsOfForeignSubsidiaries · last filed 2025-02-26
- 2024-12-31: Undistributed Earnings of Foreign Subsidiaries $1.60B.
- 2023-12-31: Undistributed Earnings of Foreign Subsidiaries $1.60B.
- 2022-12-31: Undistributed Earnings of Foreign Subsidiaries $2.70B.
- 2021-12-31: Undistributed Earnings of Foreign Subsidiaries $2.30B.
| Period end | Undistributed Earnings of Foreign Subsidiaries |
|---|---|
| 2024-12-31 | $1.60B 10-K · filed 2025-02-26 |
| 2023-12-31 | $1.60B 10-K · filed 2024-02-28 |
| 2022-12-31 | $2.70B 10-K · filed 2023-03-01 |
| 2021-12-31 | $2.30B 10-K · filed 2022-03-01 |
| 2020-12-31 | $1.90B 10-K · filed 2021-02-23 |
| 2019-12-31 | $1.60B 10-K · filed 2021-02-23 |
| 2018-12-31 | $1.20B 10-K · filed 2020-02-25 |
| 2017-12-31 | $1.70B 10-K · filed 2019-02-26 |
| 2016-12-31 | $1.20B 10-K · filed 2018-02-27 |
| 2015-12-31 | $983.80M 10-K · filed 2017-02-28 |
| 2014-12-31 | $736.90M 10-K · filed 2016-02-23 |
| 2013-12-31 | $664.30M 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |